Attendees of the 2026 Scientific Sessions will have several opportunities to engage with other diabetes professionals, starting with Friday evening’s Networking Reception.
Let the good times roll! A rich cultural character, exceptional culinary landscape, and vibrant musical traditions await in the city known as The Big Easy.
Louis J. Aronne, MD, DABOM, and Kim Gudzune, MD, MPH, led an overview of the newly developed guidance, which provides clinicians, researchers, policy makers, and others with the components of obesity care, general treatment goals, and tools to evaluate the quality of care.
Michael R. Rickels, MD, MS, and others shared results from FORWARD-101, which studied an investigational stem cell-derived, fully differentiated islet cell therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemic events.
Roomasa Channa, MD, and other panelists detailed how diabetes-related retinopathy screening programs using artificial intelligence can be cost effective and help improve adherence to screening guidelines.
Ali Aminian, MD, and Neda Rasouli, MD, weighed how the efficacy of this pharmacotherapy for the treatment of obesity impacts the role of metabolic surgery for this patient population.
Experts, including Deborah J. Wexler, MD, MSc, shared novel approaches to designing studies in diabetes health care. The importance of a collaborative approach among patients, care teams, and institutions was a common theme.
Seth A. Berkowitz, MD, MPH, and other panelists discussed the challenges facing the U.S. health care system and how policy changes could address them.
Researchers, including Ania M. Jastreboff, MD, PhD, detailed the results of a phase 2 study of maridebart cafraglutide for inducing weight loss in adults living with obesity, with or without type 2 diabetes.
Steven B. Heymsfield, MD, and other panelists discussed how bimagrumab can preserve the weight reduction seen with semaglutide while also improving body composition.